1. Home
  2. FICO vs BIIB Comparison

FICO vs BIIB Comparison

Compare FICO & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fair Isaac Corproation

FICO

Fair Isaac Corproation

HOLD

Current Price

$1,260.53

Market Cap

29.8B

ML Signal

HOLD

Logo Biogen Inc.

BIIB

Biogen Inc.

HOLD

Current Price

$215.70

Market Cap

27.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FICO
BIIB
Founded
1956
1978
Country
United States
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
29.8B
27.3B
IPO Year
1995
1996

Fundamental Metrics

Financial Performance
Metric
FICO
BIIB
Price
$1,260.53
$215.70
Analyst Decision
Buy
Buy
Analyst Count
13
25
Target Price
$1,689.92
$206.83
AVG Volume (30 Days)
300.9K
1.0M
Earning Date
04-28-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
29.78
N/A
EPS
17.73
2.15
Revenue
$1,032,475,000.00
$9,890,600,000.00
Revenue This Year
$27.28
N/A
Revenue Next Year
$16.97
N/A
P/E Ratio
$68.08
$97.60
Revenue Growth
N/A
2.22
52 Week Low
$870.01
$121.06
52 Week High
$1,998.01
$219.72

Technical Indicators

Market Signals
Indicator
FICO
BIIB
Relative Strength Index (RSI) 64.31 64.13
Support Level $1,193.10 $170.52
Resistance Level $1,323.35 N/A
Average True Range (ATR) 46.04 6.51
MACD 8.38 1.47
Stochastic Oscillator 95.15 81.38

Price Performance

Historical Comparison
FICO
BIIB

About FICO Fair Isaac Corproation

Founded in 1956, Fair Isaac Corporation is a leading applied analytics company. Fair Isaac is primarily known for its FICO credit scores, which is a widely used industry benchmark to determine the creditworthiness of an individual consumer. The firm's US-centric credit scores business accounts for most of the firm's revenue and profits and consists of business-to-business and business-to-consumer services. In addition to scores, Fair Isaac also sells software primarily to financial institutions for areas such as analytics, decision-making, customer workflows, and fraud.

About BIIB Biogen Inc.

Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Share on Social Networks: